Control during 2 years were reviewed to assess the clinical features and severity of illness, diagnostic test results, nature of complications, and causes of death. Some patients had features not usually associated with botulism including paresthesia (14%), asymmetric extremity weakness (17%), asymmetric ptosis (8%), slightly elevated cerebrospinal fluid protein values (14%), and positive responses to edrophonium chloride (26%). Several observations suggest that type A was more severe than type B disease. Although the case-fatality ratio was not significantly greater, patients with type A disease saw a physician earlier in the course of illness, were more likely to need ventilatory support, and were hospitalized longer. Patients who died were older than those who survived. Deaths within the first 2 weeks resulted from failure to recognize the severity of the disease or from pulmonary or systemic infection whereas the three late deaths were related to respirator malfunction.
BOTULISM caused by food contaminated with a neurotoxin of Clostridium botulinum is an uncommon disease in the United States. Types A and B botulinal toxin accounted for 87% of outbreaks and 91% of cases of known toxin type reported to the Centers for Disease Control (CDC) from 1970 through 1979 (1-3).
Because the disease is rare, most clinicians have never seen a case. Textbook descriptions have frequently been based on clinical data from individual botulism outbreaks (4-10) and may not provide a perspective on the range of clinical features, severity, duration, and complications of disease caused by different toxin types.
In this paper we describe the results of a systematic review of clinical records on 55 cases of types A and B food-borne botulism reported to CDC. Such an analysis allows comparison of clinical features and severity of illness, diagnostic test results, nature of complications, and causes of death and provides an assessment of the frequency of atypical clinical features.
Methods
Hospital or physician office records for each patient with botulism reported to CDC in 1973 to 1974 were reviewed, and clinical and laboratory data were recorded on a standardized form. Most records were reviewed by two of the authors; several were reviewed by other CDC physicians after instructions from the authors. Symptoms and signs were considered present if specifically noted in the record and not present only if specifically stated to be absent.
An outbreak was considered laboratory confirmed if toxin was found in the serum or stool of at least one ill patient or in the epidemiologically incriminated food by the mouse toxin neutralization test or if C. botulinum was isolated from feces of an ill person or from.implicated food (I, II, 12 The commonest symptoms were dysphagia, dry mouth, diplopia, and dysarthria (Table 1 ). Of note is that five patients with type A and three with type B botulism complained of paresthesia. Acute gastrointestinal symptoms (nausea, vomiting, abdominal cramps, or diarrhea) were present within 2 hours after onset of illness in 15 patients with type A and in 14 with type B botulism. Dysarthria, blurred vision, dyspnea, diarrhea, sore throat, and dizziness occurred significantly more frequently in patients with type A botulism.
Pupillary findings were recorded for most patients during the initial physical examination. Dilated pupils were present initially in only four of 23 patients with type A compared with 12 of 26 with type B botulism (p = 0.04); none of 24 patients with type A and nine of 27 patients with type B botulism had nonreactive pupils on initial evaluation (p = 0.002).
Weakness of the upper and lower extremities, ptosis, and hypoactive gag reflex were present in over 50% of patients with either type A or B botulism (Table 2) . Extremity weakness was asymmetric in one of -16 patients with type A and four of 14 patients with type B botulism, Electromyograms were done for 10 patients with type A and nine with type B disease; II of 13 with data available had decreased amplitute of the muscle-action potential. Eight of 13 had evidence of facilitation of the muscle-action potential after tetanic stimulation or during rapid repetitive stimulation at rates of 20/s or more; patients with type B botulism showed facilitation more frequently (p = 0.005).
THERAPY Twenty-two of the 26 patients with type A and 21 of the 29 patients with type B disease received botulinal antitoxin. Ten of the 12 patients who did not receive antitoxin either had mild illness or died before diagnosis; the other two patients had begun to recover before the diagnosis was made. OUTCOME Cardiorespiratory arrest occurred before initiation of ventilatory assistance in nine of 26 patients with type A and four of 29 with type B botulism. Nine of 13 patients who had respiratory arrest before intubation died compared with one of 15 of those intubated electirely (p == 0.001). No arrest occurred before a patient saw a physician, and only one occurred before hospitalization. Patients with type A botulism needed ventilatory support more frequently than those with type B botulism (21 of 26 versus seven of 29, p < 0.001). Although patients with type A botulism needed more prolonged ventilatory support (mean of 58 versus 26 days), the difference was not significant. Patients with type A botulism were hospitalized for a mean of 63 days compared with a mean of 21 days from those with type B disease (p < 0.03).
Seven patients with type A and three patients with type B botulism died. Patients who died were older (mean age, 57 years) than those who survived (mean age, 43 years) (p = 0.06). There was no difference in time from onset of illness to diagnosis or time from onset of illness to antitoxin therapy for fatal and nonfatal cases. Deaths within 2 weeks after onset were related to failure to recognize the gravity of the disease, or to pulmonary or systemic infection, or to both. The three deaths that occurred after 2 weeks were related to malfunction of respirators.
Discussion
Because CDC distributes botulinal antitoxin, most cases in which the diagnosis of botulism was considered were probably reported. However, some mild cases probably occurred that did not result in a visit to a physician, and diagnoses may not have been made in some severe and even fatal cases. Although the data suffer from limitations inherent in retrospective analyses of clinical records, most patients did have detailed histories and frequent recording of physical findings. Moreover, many attending physicians spoke with the authors early in the course of illness, resulting in some uniformity of clinical data.
Botulism is typically characterized by symmetric descending weakness or paralysis in the absence of sensory abnormalities. Patients are alert and afebrile early in the illness (1). Our observations, however, indicate that some patients may have atypical features and that the diagnosis should not be excluded because of one or two unexpected findings. For example, 14% of patients reported paresthesia; this sensory symptom is one that is often used to differentiate patients with Guillain-Barré syndrome from those with botulism. A similar frequency of parasthesia was noted in a recently reported type B botulism outbreak (9) . Nystagmus and ataxia were observed in 22% and 17% of patients, respectively. Asymmetry of neurologic findings, occasionally reported by others (13) , was noted in 19% of patients. Pupillary abnormalities are frequently associated with botulism; however, our data and observations of Cherington (14), who reported normal pupils in 12 of 14 patients, indicate that pupils are often normal, especially early in the illness.
Three tests used to evaluate patients with suspected botulism are lumbar puncture, the edrophonium chloride test, and electromyography. Evaluation of cerebrospinal fluid may be useful in distinguishing patients with botulism from those with Guillain-Barré syndrome, although patients with Guillain-Barré syndrome may have normal spinal fluid during the first I or 2 weeks of illness (15). Three patients in this study had slightly elevated protein levels. A similar abnormality has been reported in a patient with type E botulism whose spinal fluid protein level was 68 mg/dL (4). Data from this study and from Cherington's series (14) suggest that positive edrophonium chloride test results should not be used to eliminate the diagnosis. Electromyographic studies in patients with botulism frequently show characteristic abnormalities in clinically involved muscle groups (16, 17) . However, 15% of patients had normal muscle action potential amplitudes, and 38% lacked evidence of facilitation.
Previously reported case-fatality ratios have suggested that type A may be more severe than type B botulism (1). Both similarities and a number of important differences were noted in disease caused by the two toxin types. The age distributions, incubation periods, and frequency of hospitalization were similar. Although the case-fatality ratio was higher and patients with type A disease needed more prolonged ventilatory support, these differences were not significant. However, several observations do support the hypothesis that type A disease is more severe. Patients with type A disease saw physicians earlier in their illness, were more likely to require ventilatory support, and were hospitalized longer than those with type B disease.
The explanation for the apparent increased severity of type A compared with type B botulism is speculative. The two toxins have similar toxicity by the intraperitoneal route (18) . The difference in severity may relate to differences in amount of ingested toxin, differential absorption, differential affinity for nerve tissue receptors, or variations in host susceptibility. Type A toxin has been reported to have a greater affinity for tissue receptors (19) .
Although acute gastrointestinal symptoms have been reported to be associated with types B and E botulism (I, 4, 7), symptoms of nausea, vomiting, or diarrhea occurred early in the illness as frequently with type A as with type B disease. Patients with type A botulism were more likely to have dysarthria, blurred vision, dyspnea, diarrhea, sore throat, and dizziness. Physical findings more often associated with type A disease included arm weakness, ptosis, extraocular muscle palsies, facial nerve dysfunction, tongue weakness, and nystagmus. Patients with type B botulism were more likely to have pupillary abnormalities at initial examination and were more likely to have facilitation during rapid repetitive stimulation.
Patients who died were older than those who survived. Deaths during the first 2 weeks resulted from cardiorespiratory arrests or infection. Because no deaths occurred before physician contact, improved recognition of the disease may decrease mortality. The lower mortality rate in patients who had elective intubation suggests that early intubation for patients with impaired vital capacities may be indicated. The three late deaths were all related to malfunction of ventilators, emphasizing the need for meticulous respiratory care for patients with respiratory failure in a well-equipped intensive care unit.
